MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial
Proceedings of the National Academy of Sciences · 16.05.2023 · 120 (20)
DOI: 10.1073/pnas.2217635120 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 08.05.2023. Verfasst von Eduardo Caverzasi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94143. Hauptthemen laut MEDLINE: Remyelination, Multiple Sclerosis, White Matter. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Myelin repair is an unrealized therapeutic goal in the treatment of multiple sclerosis (MS). Uncertainty remains about the optimal techniques for assessing therapeutic efficacy and imaging biomarkers are required to measure and corroborate myelin restoration. We analyzed myelin water fraction imaging from ReBUILD, a double-blind, randomized placebo-controlled (delayed treatment) remyelination trial, that showed a significant reduction in VEP latency in patients with MS. We focused on brain regions rich in myelin. Fifty MS subjects in two arms underwent 3T MRI at baseline and months 3 and 5. Half of the cohort was randomly assigned to receive treatment from baseline through 3 mo, whereas the other half received treatment from 3 mo to 5 mo post-baseline. We computed myelin water fraction changes occurring in normal-appearing white matter of corpus callosum, optic radiations, and corticospinal tracts. An increase in myelin water fraction was documented in the normal-appearing white matter of the corpus callosum, in correspondence with the administration of the remyelinating treatment clemastine. This study provides direct, biologically validated imaging-based evidence of medically induced myelin repair. Moreover, our work strongly suggests that significant myelin repair occurs outside of lesions. We therefore propose myelin water fraction within the normal-appearing white matter of the corpus callosum as a biomarker for clinical trials looking at remyelination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94143.
- Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
- Department of Medicine, University of California, San Francisco, CA 94143.
- Department of Epidemiology & Biostatistics, University of California, San Francisco, CA 94143.
- Multimodal Imaging Physics Group, Department of Mathematics and Technology, Koblenz University of Applied Sciences, 53424 Koblenz, Germany.
- Institute for Medical Engineering and Information Processing, University of Koblenz and Landau, 56070 Koblenz, Germany.
ORCID-Profile: Eduardo Caverzasi, Nico Papinutto, Christian Cordano, Heiko Neeb, Jonah R Chan
Zitieren
APA
Caverzasi, E., Papinutto, N., Cordano, C., Kirkish, G., Gundel, T. J., Zhu, A., Akula, A. V., Boscardin, W. J., Neeb, H., Henry, R. G., Chan, J. R., & Green, A. J. (2023). MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial. Proceedings of the National Academy of Sciences, 120(20). https://doi.org/10.1073/pnas.2217635120
Vancouver
Caverzasi E, Papinutto N, Cordano C, Kirkish G, Gundel TJ, Zhu A, et al. MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial. Proceedings of the National Academy of Sciences. 2023;120(20). doi:10.1073/pnas.2217635120
BibTeX
@article{Caverzasi2023,
author = {Caverzasi, Eduardo and Papinutto, Nico and Cordano, Christian and Kirkish, Gina and Gundel, Tristan J and Zhu, Alyssa and Akula, Amit Vijay and Boscardin, W John and Neeb, Heiko and Henry, Roland G and Chan, Jonah R and Green, Ari J},
title = {MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {20},
doi = {10.1073/pnas.2217635120}
}
EUVIMED